Pharmaceutical companies face a unique challenge: AI systems must fit into some of the world's most rigorous regulatory environments, where every decision must be traceable and every data point auditable. Rather than treating AI as a completely new problem, industry leaders and regulators are discovering that the best approach is to weave AI governance into existing quality management systems that have worked for decades. By 2020, 90% of large pharmaceutical companies had already launched AI or machine learning projects, yet many are now realizing they need stronger governance frameworks to ensure these systems remain compliant, safe, and trustworthy. The pharmaceutical industry operates under extraordinarily strict rules. Every drug, device, and manufacturing process must meet standards like FDA's 21 CFR Parts 210 and 211 (Good Manufacturing Practice), Part 11 (electronic records and signatures), and ICH Q7/Q8 guidelines. These frameworks ensure data integrity through a principle called ALCOA, which stands for Attributable, Legible, Contemporaneous, Original, and Accurate, plus enduring and available (ALCOA+). When AI systems enter this world, they must generate decisions and data that meet these same standards. The challenge is that AI systems, especially those involving continuous learning or complex pattern recognition, can seem opaque and difficult to audit compared to traditional software. Recent regulatory guidance shows that agencies worldwide are converging on practical solutions. The FDA issued draft guidance in 2025 introducing a risk-based framework for assessing AI model credibility in drug submissions. The European Medicines Agency (EMA) released a reflection paper in 2023 and, jointly with the FDA in 2025, published ten "Good AI Practice" principles covering the entire medicines lifecycle. These principles emphasize rigorous risk assessment, model validation, data governance, transparency, and human oversight. The FDA has already reviewed over 500 submissions containing AI components since 2016, providing real-world evidence that AI integration in pharma is not theoretical but happening now. What Does AI Governance Actually Look Like in a Pharma Company? The most practical approach, according to industry experience, is to build AI governance on top of existing quality systems rather than creating isolated processes. AstraZeneca's approach illustrates this principle: the company harmonizes AI risk assessments with traditional quality processes, using risk tiers (low, medium, high) to scale controls appropriately. This means a low-risk AI system used for data analysis might require lighter oversight, while a high-risk system affecting clinical decisions gets intensive scrutiny. Effective AI governance in pharma requires cross-functional oversight that brings together multiple departments and perspectives. This collaborative approach ensures that AI systems are evaluated not just for technical performance but for safety, compliance, and ethical implications. Steps to Building Pharma AI Governance That Actually Works - Establish Clear Accountability: Designate senior leadership support and possibly dedicated roles such as an AI Officer or Ethics Board to oversee AI deployment across the organization and ensure accountability at the executive level. - Integrate With Existing Quality Systems: Build AI governance into current frameworks like GAMP 5 (Good Automated Manufacturing Practice) and 21 CFR Part 11 rather than creating separate processes, ensuring consistency with established quality standards. - Create Comprehensive Documentation: Maintain model cards, audit trails, and detailed records of how AI systems make decisions, ensuring procedural regularity and transparency that regulators expect. - Implement Risk-Based Controls: Use tiered risk assessment to scale oversight appropriately, applying intensive controls to high-risk systems that affect patient safety while streamlining processes for lower-risk applications. - Ensure Data Integrity and Privacy: Verify that AI systems generate data meeting ALCOA+ standards and protect patient data through strict compliance with HIPAA in the U.S. and GDPR in Europe. - Invest in Cross-Functional Training: Educate teams across R&D, quality, IT, regulatory affairs, and business functions so everyone understands AI governance principles and their role in implementation. The pharmaceutical industry has navigated similar transitions before, whenever new technologies emerged. When computerized systems became standard, when bioinformatics tools arrived, and when electronic records replaced paper, pharma adapted its governance frameworks to accommodate innovation while maintaining safety. AI is different in some ways, but the core principle remains the same: new tools must fit into existing quality structures, not replace them. Why Are Regulators Pushing This Integrated Approach? Regulators understand that isolated AI governance creates gaps and inconsistencies. When a company treats AI as a separate domain, disconnected from quality management, it risks introducing undocumented decisions, data breaches, or biased outputs that could harm patients or trigger compliance violations. The FDA, EMA, and other agencies have seen enough real-world problems to know that integration works better than isolation. One cautionary example illustrates the stakes. IBM Watson for Oncology, a high-profile AI system designed to recommend cancer treatments, faced significant challenges during rollout and was eventually discontinued in several markets. The troubled deployment underscored why strong governance is critical: without proper validation, oversight, and integration into clinical workflows, even well-intentioned AI systems can fail patients and damage trust. Data integrity is foundational to this entire effort. AI can actually improve data integrity by detecting anomalies and inconsistencies that humans might miss. However, AI systems also introduce new cybersecurity and validation challenges. An AI model trained on patient data must ensure no inadvertent leaks occur, and the model's outputs must be traceable back to the data and logic that produced them. This is where integration with existing quality systems becomes essential: pharma companies already have decades of experience protecting sensitive data and maintaining audit trails. What's Changing in 2025 and Beyond? The regulatory landscape is evolving rapidly. The FDA's 2025 draft guidance on AI model credibility represents a shift toward more explicit, risk-based frameworks. The FDA and Health Canada and the UK Medicines and Healthcare products Regulatory Agency (MHRA) consortium published "Transparency for ML-Enabled Medical Devices" in 2024, emphasizing human-centered, lifecycle transparency in AI medical devices. This means companies must be able to explain how an AI system works, what data it uses, how it was validated, and how humans remain in control of critical decisions. Globally, regulators including the MHRA, China's National Medical Products Administration (NMPA), and standards bodies like NIST, ISO, OECD, and WHO are converging on frameworks for ethical, accountable AI use in healthcare. This convergence is good news for multinational pharma companies: rather than navigating dozens of conflicting requirements, they can increasingly rely on shared principles and practices. The emergence of generative AI adds another layer of complexity. Large language models (LLMs) and other generative systems can accelerate documentation, assist in clinical trial design, and help analyze real-world data. However, they also introduce new risks around hallucinations (generating plausible-sounding but false information), bias, and transparency. Pharma companies are now extending their AI governance frameworks to cover generative AI, ensuring these powerful tools are validated and overseen just as rigorously as traditional machine learning systems. The bottom line is clear: AI governance in pharma is not a compliance checkbox or an afterthought. It is a strategic imperative that determines whether companies can safely harness AI's potential while protecting patients, data, and company integrity. By building governance into existing quality systems, establishing clear accountability, and investing in cross-functional collaboration, pharmaceutical companies can turn the question "Can we use this AI system?" into "Yes, safely". " }
